Putting the brakes on cylindromatosis?
Lakhani
Sunil R
SR
Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, and the Royal Marsden Hospital, London.
D017209:Apoptosis; D001241:Aspirin / Q000494:pharmacology* / Q000627:therapeutic use; D000074749:Deubiquitinating Enzyme CYLD; D006801:Humans; D009154:Mutation; D016328:NF-kappa B / Q000037:antagonists & inhibitors* / Q000378:metabolism; D018294:Neoplasms, Adnexal and Skin Appendage / Q000188:drug therapy; D011485:Protein Binding / Q000187:drug effects; D015398:Signal Transduction / Q000187:drug effects; D012878:Skin Neoplasms / Q000188:drug therapy; D014158:Transcription, Genetic; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism*; D025521:Tumor Suppressor Proteins / Q000235:genetics / Q000378:metabolism*; D025801:Ubiquitin / Q000378:metabolism
D016328:NF-kappa B; D014409:Tumor Necrosis Factor-alpha; D025521:Tumor Suppressor Proteins; D025801:Ubiquitin; C409984:CYLD protein, human; D000074749:Deubiquitinating Enzyme CYLD; D001241:Aspirin